Edition:
United States

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

3.16USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
70,909
52-wk High
$3.40
52-wk Low
$1.11

Chart for

About

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response... (more)

Overall

Beta: --
Market Cap(Mil.): $164.21
Shares Outstanding(Mil.): 52.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Sierra Oncology reports net loss $0.19 per share

* Qtrly ‍net loss per share, basic and diluted $0.19​ Source text for Eikon: Further company coverage:

Nov 08 2017

BRIEF-Sierra Oncology appoints Dr. Andrew Allen to board

* Sierra Oncology appoints Dr. Andrew Allen to its board of directors Source text for Eikon: Further company coverage:

Oct 25 2017

BRIEF-Sierra Oncology establishes DNA damage response advisory committee

* ‍sierra Oncology - establishes DNA damage response advisory committee​ Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Sierra Oncology reports qtrly loss per share $‍0.20​

* ‍on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018​

Aug 10 2017

Earnings vs. Estimates